RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. The company is headquartered in Aliso Viejo, California and currently employs 461 full-time employees. The company went IPO on 2021-07-30. The firm's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
Rxsight Inc の最大収益セグメントは Light Adjustable Lenses and Related Capital Equipment で、最新の利益発表における収益は 139,927,000 です。地域別に見ると、United States が Rxsight Inc の主要市場であり、収益は 139,927,000 です。